TY - JOUR
T1 - Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel
AU - Glatman-Freedman, Aharona
AU - Bromberg, Michal
AU - Hershkovitz, Yael
AU - Sefty, Hanna
AU - Kaufman, Zalman
AU - Dichtiar, Rita
AU - Keinan-Boker, Lital
N1 - Publisher Copyright:
© 2022 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2022/5
Y1 - 2022/5
N2 - We estimated vaccine effectiveness (VE) of the BNT162b2 (Pfizer-BioNTech, https://www.pfizer.com) booster dose against SARS-CoV-2 infection and reduction of complications (hospitalization, severe disease, and death) among breakthrough cases in persons in Israel >16 years of age for <20 weeks. VE estimates reached 96.8% (95% CI 96.0%–97.5%) for persons 16–59 years of age and 93.1% (95% CI 91.8%–94.2%) for persons >60 years of age on week 3. VE estimates remained at these levels for 8 weeks in the 16–59 age group and 11 weeks in those >60. A slow decline followed, becoming more pronounced in the last 2–3 weeks of evaluation. Estimates in the last week of evaluation were 77.6% (95% CI 68.4%–84.2%) and 61.3% (52.5%–68.4%) for persons 16–59 years and >60 years, respectively. The more pronounced VE decline coincided with rapid increase in Omicron variant activity. Rate reduction of breakthrough complications remained moderate to high throughout the evaluation.
AB - We estimated vaccine effectiveness (VE) of the BNT162b2 (Pfizer-BioNTech, https://www.pfizer.com) booster dose against SARS-CoV-2 infection and reduction of complications (hospitalization, severe disease, and death) among breakthrough cases in persons in Israel >16 years of age for <20 weeks. VE estimates reached 96.8% (95% CI 96.0%–97.5%) for persons 16–59 years of age and 93.1% (95% CI 91.8%–94.2%) for persons >60 years of age on week 3. VE estimates remained at these levels for 8 weeks in the 16–59 age group and 11 weeks in those >60. A slow decline followed, becoming more pronounced in the last 2–3 weeks of evaluation. Estimates in the last week of evaluation were 77.6% (95% CI 68.4%–84.2%) and 61.3% (52.5%–68.4%) for persons 16–59 years and >60 years, respectively. The more pronounced VE decline coincided with rapid increase in Omicron variant activity. Rate reduction of breakthrough complications remained moderate to high throughout the evaluation.
UR - http://www.scopus.com/inward/record.url?scp=85128800615&partnerID=8YFLogxK
U2 - 10.3201/eid2805.220141
DO - 10.3201/eid2805.220141
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35361311
AN - SCOPUS:85128800615
SN - 1080-6040
VL - 28
SP - 948
EP - 956
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 5
ER -